title: The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients.
abstract: OBJECTIVE
  To evaluate the effect of diclofenac sodium 0.1% on reducing intraocular pressure (IOP) by latanoprost 0.005% in glaucoma patients.
  
  
  METHODS
  Twenty-two patients with bilateral primary open angle glaucoma were enrolled in this study. All patients had been given only latanoprost for at least 4 weeks. Topical diclofenac sodium was additionally applied to one eye (dicloptin group), whereas hydroxypropyl methyl cellulose was administered into the other eye (control group); both 4 times a day for 2 weeks. IOP measurement was performed before and 2 weeks after the administrations, and also 2 weeks after discontinuing additional ophthalmic solutions.
  
  
  RESULTS
  No significant difference was observed in the IOPs before additional administration of ophthalmic solution between the dicloptin group and the control group (P=0.47). Additional administration of diclofenac sodium increased mean IOP from 15.73±1.75 to 17.32±2.23 mm Hg (P=0.01). This increase was reversed 2 weeks after discontinuing additional solutions (P=0.80); however, no significant difference in mean IOP was observed in the control group after administration and after discontinuing the additional medication (P=0.94 and 0.84, respectively).
  
  
  CONCLUSIONS
  Topical diclofenac sodium may interfere with the IOP lowering effect of latanoprost in glaucoma patients; therefore this interference should be noted in coadministration of these drugs.
authors.affiliation: Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Rana
authors.initials: R
authors.lastname: Sorkhabi
authors.forename: Rakhshande
authors.initials: R
authors.lastname: Alipanahi
authors.forename: Amir
authors.initials: A
authors.lastname: Eftakhari-Milani
authors.forename: Leila
authors.initials: L
authors.lastname: Ghojazadeh
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000075202:Contraindications; D004008:Diclofenac / Q000008:administration & dosage*; D004347:Drug Interactions; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D014065:Tonometry, Ocular
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D004008:Diclofenac; D000077338:Latanoprost